20:31 , Aug 16, 2019 |  BC Extra  |  Company News

Celgene’s myelofibrosis approval sets up key launch for BMS

FDA's approval of potential blockbuster Inrebic fedratinib from Celgene sets up a key launch for BMS in myelofibrosis, an indication for which only one other drug is marketed in the U.S. The agency's decision also...
00:09 , Jun 4, 2019 |  BC Innovations  |  Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified gemcitabine, Jevtana cabazitaxel and Jakavi ruxolitinib as drugs that could help treat pediatric AML. High throughput screening of a library of...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
17:59 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

FDA grants Priority Review to Incyte's Jakafi for acute GvHD

Incyte Corp. (NASDAQ:INCY) said FDA accepted and granted Priority Review to an sNDA seeking approval for Jakafi ruxolitinib to treat acute graft-versus-host disease (GvHD) in patients with inadequate response to corticosteroids. The PDUFA date was...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
19:22 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Incyte's Jakafi meets in Phase II for steroid-refractory GvHD

Incyte Corp. (NASDAQ:INCY) said Jakafi ruxolitinib in combination with corticosteroids met the primary endpoint in the U.S. Phase II REACH1 trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company plans to submit an sNDA...
19:06 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib...
16:32 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

JAKs and clots

Brigham and Women’s Hospital researchers have uncovered the mechanisms behind a major complication in bone marrow disorders by linking a JAK-2 mutation with thrombosis in patients and mice, and identified a way to treat blood...